Back to search results

A Study on Blood Cell Growth and Heart Health After Hodgkin Lymphoma Treatment

This study is looking at how patterns of blood cell growth, called clonal hematopoiesis (t-CH), are connected to heart health in people who were treated for Hodgkin lymphoma when they were younger. Sometimes, cancer treatments received at a young age can lead to heart problems later on. Researchers want to see if specific changes in blood cells (t-CH) can help predict who might be at higher risk for heart issues. If doctors can identify these risks early, they can monitor patients more closely to prevent or find heart problems sooner. You would undergo collection of archived blood samples, new blood samples, medical record review, an MRI, and complete surveys. The study aims to understand the prevalence of t-CH linked to heart disease up to one year after treatment.

Study design
This is an observational study, meaning participants are observed without receiving new treatments. It plans to enroll 190 participants.
What's involved
You would undergo collection of archived blood samples, new blood samples, medical record review, an MRI, and complete surveys.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures therapy-related clonal hematopoiesis (t-CH) up to 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05705531

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Recruiting
Not specifiedAges 7+Observational
Children's Oncology Group
~190 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:Archive Sample RetrievalBiospecimen CollectionElectronic Health Record ReviewMagnetic Resonance ImagingSurvey Administration

At a glance

Recruiting sites
35 of 36 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Therapy-related clonal hematopoiesis (t-CH) with mutations associated with cardiovascular disease
Measured over Up to 1 year

Conditions

Cardiovascular Disorder
Classic Hodgkin Lymphoma
Clonal Hematopoiesis

Explore related trials

Cardiovascular DisorderClassic Hodgkin LymphomaClonal Hematopoiesis

Where it's being run

36 sites across 24 states
Florida6
Texas3
California2
Connecticut2
New York2
Ohio2
Pennsylvania2
Alabama1

Study leadership

  • Robert J Hayashi · PRINCIPAL_INVESTIGATOR · Children's Oncology Group

Who to contact

Site Public Contact
800-388-8721
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient must be \>= 7 years of age at the time of enrollment (age to perform an MRI without sedation).
History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was \>= 2 and \< 22 years of age.
As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg/m\^2 as estimated in doxorubicin isotoxic equivalents dose conversion calculation.
Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose.
All systemic cancer treatment must have been completed ≥ 2 years prior to study enrollment.
Not known to have had a primary event (relapse/second malignancy/death).
Note: Subjects treated at another institution are eligible if they are now being followed at the current COG institution, if the study procedures can be performed and the data accessible by a COG institution where the study is open.
Patient must have access to cardiac MRI at the enrolling institution and must be able to complete cardiac MRI without sedation.

Exclusion

Medical contraindication to undergoing a non-contrast cardiac MRI.
Patients with nodular lymphocyte-predominant HL.
Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).
History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL.
Note: exceptions are made for congenital conditions considered fully resolved by surgery and chronic conditions such as hypertension or hypercholesterolemia that are managed with medical intervention.
History of an immunodeficiency that existed prior to cHL diagnosis, such as primary immunodeficiency syndromes, organ transplant recipients and conditions requiring systemic immunosuppressive agents.

What this trial measures

  • Therapy-related clonal hematopoiesis (t-CH) with mutations associated with cardiovascular diseaseUp to 1 year

    Measured in the blood of eligible participants who were previously treated with anthracycline-containing therapy for pediatric classical Hodgkin lymphoma.